Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
195 hedge funds and large institutions have $2.4B invested in Impax Laboratories, Inc. in 2015 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 68 increasing their positions, 80 reducing their positions, and 31 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
3% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 31
1% less funds holding
Funds holding: 197 → 195 (-2)
15% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 80
24% less capital invested
Capital invested by funds: $3.16B → $2.4B (-$760M)
25% less call options, than puts
Call options by funds: $3.93M | Put options by funds: $5.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hound Partners
New York
|
+$67.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$34M |
| 3 |
HCM
Hayman Capital Management
Dallas,
Texas
|
+$27.3M |
| 4 |
AG
Aravt Global
New York
|
+$20M |
| 5 |
BP
Banbury Partners
Charlotte,
North Carolina
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$49.6M |
| 2 |
HM
HealthCor Management
New York
|
-$25.3M |
| 3 |
Tiger Global Management
New York
|
-$19.7M |
| 4 |
BJCM
Blue Jay Capital Management
Los Angeles,
California
|
-$14.9M |
| 5 |
SCA
Southpoint Capital Advisors
New York
|
-$13.5M |
IPXL Hedge Fund Activity: Q3 2015 in Review
195 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q3 2015, worth a combined $2.4B — down 24% from $3.16B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of IPXL and 30 opened new positions — a net loss of 1 holder — while 80 trimmed existing stakes and 68 added.
The largest buyer was Hound Partners, adding an estimated $67.5M. The largest seller was Slate Path Capital, cutting an estimated $49.6M.
- 195 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q3 2015, down from 197 in Q2 2015.
- Funds reported $2.4B of Impax Laboratories, Inc. stock for Q3 2015, down 24% quarter-over-quarter.
- 30 funds opened new Impax Laboratories, Inc. positions in Q3 2015 and 31 closed out, a net change of -1 holder.
- The largest Impax Laboratories, Inc. buyer in Q3 2015 was Hound Partners, an estimated $67.5M added.
- The largest Impax Laboratories, Inc. seller in Q3 2015 was Slate Path Capital, an estimated $49.6M sold.
Based on aggregated 13F filings for Q3 2015.